In this short video, Dr. Jennifer Carlisle discusses the safety of HER2-targeted antibody-drug conjugates in patients with NSCLC.

Take the Survey

Supported by an educational grant from Daiichi Sankyo.

Leave a Comment

Please confirm that you are not a robot.